These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19211579)

  • 1. Factor V Leiden in Mexico.
    Ruiz-Arguelles GJ
    Clin Appl Thromb Hemost; 2009; 15(3):366. PubMed ID: 19211579
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of factor V Leiden and prothrombin 20210A mutations in indigenous Australians.
    Bennett JA; Palmer LJ; Musk AW; Erber WN
    Thromb Haemost; 2001 Dec; 86(6):1592-3. PubMed ID: 11776339
    [No Abstract]   [Full Text] [Related]  

  • 3. High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary.
    Balogh I; Póka R; Losonczy G; Muszbek L
    Thromb Haemost; 1999 Nov; 82(5):1555-6. PubMed ID: 10595655
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ramírez-Cisneros FJ
    Am J Hematol; 2001 Jan; 66(1):28-31. PubMed ID: 11426488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How old is factor V Leiden mutation?
    Pawar AR; Shetty S; Ghosh K; Mohanty D
    Thromb Haemost; 2001 Dec; 86(6):1591-2. PubMed ID: 11776338
    [No Abstract]   [Full Text] [Related]  

  • 6. Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
    Okada H; Toyoda Y; Takagi A; Saito H; Kojima T; Yamazaki T
    Int J Hematol; 2010 Apr; 91(3):549-50. PubMed ID: 20300981
    [No Abstract]   [Full Text] [Related]  

  • 7. The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia.
    Bôžiková A; Gabriková D; Sovičová A; Behulová R; Mačeková S; Boroňová I; Petrejčíková E; Soták M; Bernasovská J; Bernasovský I
    J Thromb Thrombolysis; 2012 Oct; 34(3):406-9. PubMed ID: 22562116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of Factor V Leiden in three ethnic groups of patients with deep vein thrombosis in the Western Cape province of South Africa.
    Rubinstein R; Kolia F; Novitzky N
    Eur J Haematol; 2000 Jul; 65(1):78-9. PubMed ID: 10914945
    [No Abstract]   [Full Text] [Related]  

  • 10. Factor V Leiden haplotypes in two homozygotes of Asian origin.
    Rees DC; Clarke K; Martin PG; Keeling DM
    Br J Haematol; 1998 Sep; 102(5):1381-2. PubMed ID: 9753076
    [No Abstract]   [Full Text] [Related]  

  • 11. Futility of testing for factor V Leiden.
    Favaloro EJ; McDonald D
    Blood Transfus; 2012 Jul; 10(3):260-3. PubMed ID: 22889816
    [No Abstract]   [Full Text] [Related]  

  • 12. A dangerous combination: Fabry disease and factor V Leiden.
    Niemann M; Weidemann F
    Intern Med J; 2012 Nov; 42(11):1270-1. PubMed ID: 23157526
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 14. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 15. Utility of testing for factor V Leiden.
    Franchini M
    Blood Transfus; 2012 Jul; 10(3):257-9. PubMed ID: 22889815
    [No Abstract]   [Full Text] [Related]  

  • 16. [Idiopathic intracranial hypertension and factor V Leiden mutation].
    Younes S; Aissi M; Chérif Y; Daoussi N; Boughammoura A; Frih Ayed M; Sfar MH; Jerbi S
    J Mal Vasc; 2014 Jul; 39(4):270-3. PubMed ID: 24908418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
    Zavala Hernández C; Hernández Zamora E; Martínez Murillo C; Arenas Sordo Mde L; González Orozco AE; Reyes Maldonado E
    Cir Cir; 2010; 78(2):127-32. PubMed ID: 20478113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor V Leiden: to test or not to test, that is the debate.
    Makris M
    Blood Transfus; 2012 Jul; 10(3):255-6. PubMed ID: 22889814
    [No Abstract]   [Full Text] [Related]  

  • 19. Interpreting results from Factor V Leiden mutation analysis: a cautionary note.
    Sinclair GD; Poon MC
    Clin Appl Thromb Hemost; 2013; 19(1):106-7. PubMed ID: 23034579
    [No Abstract]   [Full Text] [Related]  

  • 20. Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
    Verdú A; Cazorla MR; Granados MA; Alonso JA; Casado LF
    Pediatr Neurol; 2001 Jan; 24(1):69-71. PubMed ID: 11182285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.